<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="590">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267980</url>
  </required_header>
  <id_info>
    <org_study_id>Inonu 2</org_study_id>
    <nct_id>NCT02267980</nct_id>
  </id_info>
  <brief_title>Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy</brief_title>
  <official_title>Turgut Ozal Medical Center Department of Anesthesiology and Reanimation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluate the effects of a subanesthetic dose of ketamine, administered as
      an adjunct to sevoflurane, on duration of seizure activity, hemodynamic profile and recovery
      times during electroconvulsive therapy (ECT) in patients with major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will randomly allocate, to either a sevoflurane-ketamine (Group SK),
      sevoflurane-saline (Group SS) receiving group. Mean arterial pressure (MAP) and heart rate
      (HR) will record prior to anesthetic induction (T1); following anesthetic induction (T2);
      and 0, 1, 3, and 10 min after the seizure has ended (T3, T4, T5, and T6, respectively).
      Motor and EEG seizure durations will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>seizure duration</measure>
    <time_frame>During electroconvulsive therapy (30 minutes)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the time from application of the ECT stimulus to the cessation of tonic-clonic motor activity in the isolated arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP)</measure>
    <time_frame>During Electroconvulsive therapy (30 minutes)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean arterial pressure (MAP) will be recorded prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 min after the seizure has ended (T3, T4, T5, and T6, respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR)</measure>
    <time_frame>During Electroconvulsive therapy (30 minutes)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Heart rate (HR) will be recorded prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 min after the seizure has ended (T3, T4, T5, and T6, respectively).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Group SK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group SS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Inhalation anesthetic agent</description>
    <arm_group_label>Group SK</arm_group_label>
    <arm_group_label>Group SS</arm_group_label>
    <other_name>Sevoflurane (sevorane)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intravenous anesthetic agent</description>
    <arm_group_label>Group SK</arm_group_label>
    <other_name>Ketamine (Ketalar) 50mg/mL injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Isotonic solution for placebo group</description>
    <arm_group_label>Group SS</arm_group_label>
    <other_name>Isotonic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive patients

        Exclusion Criteria:

          -  Pregnancy

          -  Have a history of myocardial infarction in the previous six months

          -  Atrial fibrillation or flutter

          -  Heart block

          -  Unregulated hypertension

          -  Cerebrovascular diseases

          -  A known drug allergy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feray Erdil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feray Erdil, MD</last_name>
    <phone>904223410660</phone>
    <phone_ext>3148</phone_ext>
    <email>feray.erdil@inonu.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmut Durmus, MD</last_name>
    <phone>904223410660</phone>
    <phone_ext>3105</phone_ext>
    <email>mahmut.durmus@inonu.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turgut Ozal Medical Center</name>
      <address>
        <city>Malatya</city>
        <zip>44315</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmut Durmus, Prof Dr</last_name>
      <phone>904223410660</phone>
      <phone_ext>3105</phone_ext>
      <email>mahmut.durmus@inonu.edu.tr</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Yalcin S, Aydoğan H, Selek S, Kucuk A, Yuce HH, Karababa F, Bilgiç T. Ketofol in electroconvulsive therapy anesthesia: two stones for one bird. J Anesth. 2012 Aug;26(4):562-7. doi: 10.1007/s00540-012-1378-6. Epub 2012 May 24.</citation>
    <PMID>22623080</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 15, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Feray Erdil</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Electroconvulsive therapy; sevoflurane; ketamine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
